ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. T… Read more
ARS Pharmaceuticals, Inc (SPRY) - Total Assets
Latest total assets as of September 2025: $372.80 Million USD
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) holds total assets worth $372.80 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ARS Pharmaceuticals, Inc - Total Assets Trend (2018–2024)
This chart illustrates how ARS Pharmaceuticals, Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ARS Pharmaceuticals, Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
ARS Pharmaceuticals, Inc's total assets of $372.80 Million consist of 95.2% current assets and 4.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.5% |
| Accounts Receivable | $9.16 Million | 2.6% |
| Inventory | $5.21 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.68 Million | 2.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how ARS Pharmaceuticals, Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ARS Pharmaceuticals, Inc's current assets represent 95.2% of total assets in 2024, an increase from 75.4% in 2018.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2024, down from 73.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 2.6% of total assets.
ARS Pharmaceuticals, Inc Competitors by Total Assets
Key competitors of ARS Pharmaceuticals, Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
ARS Pharmaceuticals, Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ARS Pharmaceuticals, Inc generates 0.25x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, ARS Pharmaceuticals, Inc generates $ 2.28 in net profit.
ARS Pharmaceuticals, Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.66 | 12.56 | 40.69 |
| Quick Ratio | 6.51 | 12.52 | 40.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $287.99 Million | $ 192.17 Million | $ 381.06 Million |
ARS Pharmaceuticals, Inc - Advanced Valuation Insights
This section examines the relationship between ARS Pharmaceuticals, Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.92 |
| Latest Market Cap to Assets Ratio | 2.49 |
| Asset Growth Rate (YoY) | 50.6% |
| Total Assets | $351.15 Million |
| Market Capitalization | $874.81 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values ARS Pharmaceuticals, Inc's assets at a significant premium ( 2.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: ARS Pharmaceuticals, Inc's assets grew by 50.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ARS Pharmaceuticals, Inc (2018–2024)
The table below shows the annual total assets of ARS Pharmaceuticals, Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $351.15 Million | +50.59% |
| 2023-12-31 | $233.19 Million | -17.14% |
| 2022-12-31 | $281.44 Million | +358.02% |
| 2021-12-31 | $61.45 Million | +132.69% |
| 2020-12-31 | $26.41 Million | +68.77% |
| 2019-12-31 | $15.65 Million | -43.20% |
| 2018-12-31 | $27.55 Million | -- |